{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:16:20Z","timestamp":1759482980491},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1208\/s12248-020-00485-6","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T18:05:46Z","timestamp":1596477946000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan"],"prefix":"10.1208","volume":"22","author":[{"given":"Pierre-Eric","family":"Juif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Voors-Pette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Ufer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"issue":"4","key":"485_CR1","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.1097\/00004872-198812040-00056","volume":"6","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl. 1988;6(4):S188\u201391.","journal-title":"J Hypertens Suppl"},{"issue":"8676","key":"485_CR2","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/S0140-6736(89)92019-9","volume":"2","author":"H Masaoka","year":"1989","unstructured":"Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet. 1989;2(8676):1402.","journal-title":"Lancet."},{"issue":"3","key":"485_CR3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/WNF.0000000000000085","volume":"38","author":"R Behrouz","year":"2015","unstructured":"Behrouz R, Sadat-Hosseiny Z. Pharmacological agents in aneurysmal subarachnoid hemorrhage: successes and failures. Clin Neuropharmacol. 2015;38(3):104\u20138.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"485_CR4","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","volume":"43","author":"ES Connolly Jr","year":"2012","unstructured":"Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2012;43(6):1711\u201337.","journal-title":"Stroke."},{"issue":"6","key":"485_CR5","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/STROKEAHA.111.648980","volume":"43","author":"RL Macdonald","year":"2012","unstructured":"Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43(6):1463\u20139.","journal-title":"Stroke."},{"issue":"11","key":"485_CR6","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1161\/STROKEAHA.108.519942","volume":"39","author":"RL Macdonald","year":"2008","unstructured":"Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39(11):3015\u201321.","journal-title":"Stroke."},{"key":"485_CR7","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/j.wneu.2018.11.143","volume":"123","author":"J Song","year":"2019","unstructured":"Song J, Xue YQ, Wang YJ, Xu P, Sun DK, Chen W. An update on the efficacy and safety profile of clazosentan in cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. World Neurosurg. 2019;123:e235\u2013e44.","journal-title":"World Neurosurg"},{"issue":"2","key":"485_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00228-006-0117-z","volume":"63","author":"PL van Giersbergen","year":"2007","unstructured":"van Giersbergen PL, Dingemanse J. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist. Eur J Clin Pharmacol. 2007;63(2):151\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"485_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5414\/CPP47169","volume":"47","author":"PL van Giersbergen","year":"2009","unstructured":"van Giersbergen PL, Treiber A, Dingemanse J. In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans. Int J Clin Pharmacol Ther. 2009;47(3):169\u201377.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"485_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0092-8674(95)90340-2","volume":"81","author":"MC Sanguinetti","year":"1995","unstructured":"Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81(2):299\u2013307.","journal-title":"Cell."},{"issue":"5220","key":"485_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1126\/science.7604285","volume":"269","author":"MC Trudeau","year":"1995","unstructured":"Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995;269(5220):92\u20135.","journal-title":"Science."},{"issue":"5","key":"485_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/cts.12639","volume":"12","author":"PE Juif","year":"2019","unstructured":"Juif PE, Voors-Pette C, Ufer M, Dogterom P, Dingemanse J. Influence of rifampin-mediated organic anion-transporting polypeptide 1B1\/1B3 inhibition on the pharmacokinetics of clazosentan. Clin Transl Sci. 2019;12(5):440\u20134.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"485_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, Ferber G, Huang D, Liu J, et al. Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn. 2018;45(3):383\u201397.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"485_CR14","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs \u2014 Questions and Answers (R3) Revision 2. June 2017."},{"issue":"4","key":"485_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/anec.12227","volume":"20","author":"G Ferber","year":"2015","unstructured":"Ferber G, Zhou M, Darpo B. Detection of QTc effects in small studies--implications for replacing the thorough QT study. Ann Noninvasive Electrocardiol. 2015;20(4):368\u201377.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"7","key":"485_CR16","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1177\/0091270010378408","volume":"51","author":"CW Tornoe","year":"2011","unstructured":"Tornoe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV. Creation of a knowledge management system for QT analyses. J Clin Pharmacol. 2011;51(7):1035\u201342.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"485_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jcph.1283","volume":"59","author":"J Taubel","year":"2019","unstructured":"Taubel J, Ferber G, Fernandes S, Camm AJ. Diurnal profile of the QTc interval following moxifloxacin administration. J Clin Pharmacol. 2019;59(1):35\u201344.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"485_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/jcph.933","volume":"57","author":"B Cirincione","year":"2017","unstructured":"Cirincione B, Sager PT, Mager DE. Influence of meals and glycemic changes on QT interval dynamics. J Clin Pharmacol. 2017;57(8):966\u201376.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"485_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/jcph.1129","volume":"58","author":"JR Turner","year":"2018","unstructured":"Turner JR, Rodriguez I, Mantovani E, Gintant G, Kowey PR, Klotzbaugh RJ, et al. Drug-induced proarrhythmia and torsade de pointes: a primer for students and practitioners of medicine and pharmacy. J Clin Pharmacol. 2018;58(8):997\u20131012.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"485_CR20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1517\/14656566.2012.682150","volume":"13","author":"RB Raffa","year":"2012","unstructured":"Raffa RB, Burmeister JJ, Yuvasheva E, Pergolizzi JV Jr. QTc interval prolongation by d-propoxyphene: what about other analgesics? Expert Opin Pharmacother. 2012;13(10):1397\u2013409.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"485_CR21","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00228-015-1959-z","volume":"71","author":"RR Shah","year":"2015","unstructured":"Shah RR, Maison-Blanche P, Duvauchelle T, Robert P, Denis E. Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study. Eur J Clin Pharmacol. 2015;71(12):1451\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"485_CR22","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1177\/0091270010381498","volume":"51","author":"JA Florian","year":"2011","unstructured":"Florian JA, Tornoe CW, Brundage R, Parekh A, Garnett CE. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol. 2011;51(8):1152\u201362.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"485_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1358\/dot.2000.36.4.570201","volume":"36","author":"PA Moise","year":"2000","unstructured":"Moise PA, Birmingham MC, Schentag JJ. Pharmacokinetics and metabolism of moxifloxacin. Drugs Today (Barc). 2000;36(4):229\u201344.","journal-title":"Drugs Today (Barc)"},{"issue":"5","key":"485_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/FJC.0b013e3182a2630d","volume":"62","author":"CL Green","year":"2013","unstructured":"Green CL, Whellan DJ, Lambe L, Bellibas SE, Wijngaard P, Prats J, et al. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. J Cardiovasc Pharmacol. 2013;62(5):466\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"485_CR25","doi-asserted-by":"publisher","first-page":"e02385","DOI":"10.1128\/AAC.02385-16","volume":"61","author":"M Hossain","year":"2017","unstructured":"Hossain M, Zhou M, Tiffany C, Dumont E, Darpo B. A phase I, randomized, double-blinded, placebo- and moxifloxacin-controlled, four-period crossover study to evaluate the effect of gepotidacin on cardiac conduction as assessed by 12-lead electrocardiogram in healthy volunteers. Antimicrob Agents Chemother. 2017;61(5):e02385\u201316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"485_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/bcp.13128","volume":"83","author":"J Taubel","year":"2017","unstructured":"Taubel J, Ferber G, Fox G, Fernandes S, Lorch U, Camm AJ. Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. Br J Clin Pharmacol. 2017;83(2):339\u201348.","journal-title":"Br J Clin Pharmacol"},{"key":"485_CR27","unstructured":"EMA. Assessment report for Volibris. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/volibris-epar-public-assessment-report_en.pdf 2008. Accessed 17 June 2020."},{"issue":"3","key":"485_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1023\/A:1023961004016","volume":"8","author":"TM Kolettis","year":"2003","unstructured":"Kolettis TM, Kyriakides ZS, Leftheriotis D, Papalambrou A, Kremastinos DT, Webb DJ. Electrophysiologic effects of endothelin receptor-a blockade in patients with coronary artery disease. J Interv Card Electrophysiol. 2003;8(3):173\u20139.","journal-title":"J Interv Card Electrophysiol"},{"issue":"4","key":"485_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCHEARTFAILURE.109.917781","volume":"3","author":"MG Link","year":"2010","unstructured":"Link MG, Yan GX, Kowey PR. Evaluation of toxicity for heart failure therapeutics: studying effects on the QT interval. Circ Heart Fail. 2010;3(4):547\u201355.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"485_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pupt.2014.04.007","volume":"29","author":"N Lindegger","year":"2014","unstructured":"Lindegger N, Sidharta PN, Reseski K, Dingemanse J. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects. Pulm Pharmacol Ther. 2014;29(1):41\u20138.","journal-title":"Pulm Pharmacol Ther"},{"key":"485_CR31","unstructured":"FDA. Oliceridine Briefing Document. FDA Advisory Committee Meeting. https:\/\/www.fda.gov\/media\/121230\/download. 2018. Accessed 17 June 2020."},{"key":"485_CR32","unstructured":"Trevena Receives Complete Response Letter for Oliceridine from FDA. https:\/\/www.drugs.com\/nda\/olinvo_181102.html. 2018. Accessed 17 June 2020."},{"key":"485_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","volume":"81","author":"T Colatsky","year":"2016","unstructured":"Colatsky T, Fermini B, Gintant G, Pierson JB, Sager P, Sekino Y, et al. The comprehensive in vitro proarrhythmia assay (CiPA) initiative - update on progress. J Pharmacol Toxicol Methods. 2016;81:15\u201320.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"485_CR34","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1097\/00000542-200506000-00006","volume":"102","author":"B Charbit","year":"2005","unstructured":"Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005;102(6):1094\u2013100.","journal-title":"Anesthesiology."},{"key":"485_CR35","unstructured":"Rose BD, Post TW. Clinical physiology of acid-base and electrolyte disorders. In: McGraw-Hill NY, editor. 5th edition ed 2001. p. 836\u201356."},{"issue":"11","key":"485_CR36","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1681\/ASN.2011040414","volume":"22","author":"PS Aronson","year":"2011","unstructured":"Aronson PS, Giebisch G. Effects of pH on potassium: new explanations for old observations. J Am Soc Nephrol. 2011;22(11):1981\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"485_CR37","first-page":"12","volume":"7","author":"P Widimsky","year":"2008","unstructured":"Widimsky P. Hypokalemia and the heart. e-J Cardiol Pract. 2008;7(9):12.","journal-title":"e-J Cardiol Pract"},{"issue":"4","key":"485_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/1574884713666180223123947","volume":"12","author":"CV Etchegoyen","year":"2017","unstructured":"Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G. Drug-induced QT interval prolongation in the intensive care unit. Curr Clin Pharmacol. 2017;12(4):210\u201322.","journal-title":"Curr Clin Pharmacol"},{"key":"485_CR39","doi-asserted-by":"crossref","unstructured":"Gibaldi M, Perrier D. Pharmacokinetics New York: Marcel Dekker; 1982.","DOI":"10.1201\/b14095"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00485-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-020-00485-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00485-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T23:10:51Z","timestamp":1627945851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-020-00485-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["485"],"URL":"https:\/\/doi.org\/10.1208\/s12248-020-00485-6","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"19 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed according to good clinical practice and in accordance with the principles of the Declaration of Helsinki, and written informed consent was obtained from each subject prior to any study procedure. The protocol was approved by the Ethics Committee (Medisch Ethische Toetsings Commissie, Assen, The Netherlands).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"PEJ, JD, and MU are employees of Idorsia Pharmaceuticals Ltd., the sponsor of the study, and possess stock options\/shares. CVP had support from QPS for the submitted work and was employed by QPS in the previous 3\u00a0years.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"103"}}